Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07363720 · ClinicalTrials.gov registry record · Phase 3
A Trial of TAK-861 for the Treatment of Narcolepsy With Cataplexy
A Phase 3 study of Narcolepsy With Cataplexy and Narcolepsy Type 1 (NT1), sponsored by Takeda.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 88
- Enrollment target
- 7
- Study locations
NCT07363720 is a Phase 3 study of Narcolepsy With Cataplexy and Narcolepsy Type 1 (NT1) that is actively recruiting participants, run by Takeda. The registered enrollment target is 88 participants. The trial reports 7 study locations across 6 states.
The verdict
NCT07363720, a Phase 3 study of Narcolepsy With Cataplexy and Narcolepsy Type 1 (NT1), is actively recruiting participants, sponsored by Takeda.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 88 participants
- Enrollment target
- 7
- Study locations
Study Summary
The main aim of this study is to assess how effective TAK-861 is for treating narcolepsy type 1 and if this effect is maintained over time. Participants will take TAK-861 for a few months and if they meet certain criteria, they will be randomly assigned (by chance, like flipping a coin) to continue taking TAK-861 or take placebo (fake medicine) for up to 4 weeks to see if their narcolepsy symptoms return.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG TAK-861
Study Locations (7)
Florida
- Takeda Site 4 - Brandon
- Takeda Site 6 - Miami
California
- Takeda Site 1 - Redwood City
Michigan
- Takeda Site 7 - Southfield
Ohio
- Takeda Site 2 - Cincinnati
South Carolina
- Takeda Site 3 - Columbia
Texas
- Takeda Site 5 - Austin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 88 participants |
| Start Date | 2026-01-29 |
| Est. Completion | 2026-10-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07363720
The ClinicalTrials.gov registry entry for NCT07363720 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 88 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Narcolepsy With Cataplexy appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07363720 reports 7 study locations spanning 6 distinct geographic areas - top geographies include Florida, California, Michigan.
Frequently Asked Questions
What is clinical trial NCT07363720 about?
NCT07363720 is a clinical study titled "A Trial of TAK-861 for the Treatment of Narcolepsy With Cataplexy". The main aim of this study is to assess how effective TAK-861 is for treating narcolepsy type 1 and if this effect is maintained over time. Participants will take TAK-861 for a few months and if they meet certain criteria, they will be randomly assigned (by chance, like flipping a coin) to continue ...
What is the current status of trial NCT07363720?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 88 participants. The study started on 2026-01-29. Estimated completion is 2026-10-02.
What conditions does trial NCT07363720 study?
This clinical trial studies the following conditions: Narcolepsy With Cataplexy, Narcolepsy Type 1 (NT1).
What interventions are being tested in trial NCT07363720?
The interventions under investigation include: Placebo (DRUG), TAK-861 (DRUG).
Who is sponsoring clinical trial NCT07363720?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07363720 being conducted?
This trial has 7 study locations across California, Florida, Michigan, Ohio, South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Narcolepsy With Cataplexy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.